科伦博泰生物(06990)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06990 科伦博泰生物

未开盘 09-08 16:08:36

488.000

-2.400

-0.49%

最高494.600	最低478.600	成交量31.14万
今开483.000	昨收490.400	日振幅3.26%
总市值1,166亿	流通市值863.76亿	总股本2.39亿
成交额1.51亿	换手率0.18%	流通股本1.77亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06990","market":"HK","secType":"STK","nameCN":"科伦博泰生物","latestPrice":488,"timestamp":1788854916011,"preClose":490.4,"halted":0,"volume":311400,"delay":0,"changeRate":-0.004893964110929807,"floatShares":177000000,"shares":239000000,"eps":-1.9373141552769217,"marketStatus":"未开盘","change":-2.4,"latestTime":"09-08 16:08:36","open":483,"high":494.6,"low":478.6,"amount":151283620,"amplitude":0.032626,"askPrice":488,"askSize":800,"bidPrice":487,"bidSize":2500,"shortable":3,"etf":0,"ttmEps":0.7579592694252981,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788917400000},"marketStatusCode":0,"adr":0,"listingDate":1689004800000,"exchange":"SEHK","adjPreClose":490.4,"openAndCloseTimeList":[[1788831000000,1788840000000],[1788843600000,1788854400000]],"volumeRatio":0.69869,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06990","defaultTab":"news","newsList":[{"id":"2665320030","title":"科伦博泰生物：POLARIS-1的2期部分取得阳性中期结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320030","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665320030?lang=zh_cn&edition=full","pubTime":"2026-09-08 20:20","pubTimestamp":1788870014,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["06990","LU0196878994.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131010373","title":"科伦博泰生物：TSLP 抗体新药 SKB378/WIN378 哮喘 2 期试验获阳性数据，3 期临床启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1131010373","media":"公告速递","labels":["productRelease","dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131010373?lang=zh_cn&edition=full","pubTime":"2026-09-08 20:11","pubTimestamp":1788869510,"startTime":"0","endTime":"0","summary":"2026年9月8日，科伦博泰生物医药股份有限公司公告称，其合作方 Windward Bio AG 公布的 TSLP 靶向全人源超长效单克隆抗体 SKB378/WIN378 在治疗哮喘的全球无缝 2/3 期临床研究 POLARIS-1中取得阳性 2 期中期结果，并已启动 3 期研究。主要评估皮下注射 SKB378/WIN378 三个剂量与安慰剂的药代动力学、安全性、免疫原性及药效学活性，并为 3 期剂量选择提供依据，同时监测对肺功能及气道炎症生物标志物的影响。公司提醒投资者，SKB378/WIN378 最终不一定能够成功开发及商业化，请投资者注意投资风险。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101577692","title":"科伦博泰生物：Polaris-2三期临床试验第二阶段计划于2027年上半年启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1101577692","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101577692?lang=zh_cn&edition=full","pubTime":"2026-09-08 20:07","pubTimestamp":1788869230,"startTime":"0","endTime":"0","summary":"科伦博泰生物宣布，其Polaris-2三期临床试验的第二阶段计划于2027年上半年正式启动。这一时间表的确定，标志着该公司在药物研发管线上迈出了关键一步。据悉，Polaris-2是科伦博泰生物重点推进的临床项目之一，此次公布的启动计划延续了公司此前披露的研发节奏。需要指出的是，药物研发具有高度不确定性，实际启动时间仍可能受到监管审批、患者入组速度等多重因素影响。因此，后续公告仍然值得持续跟踪。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0196878994.USD","BK1161","06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123875780","title":"科伦博泰生物合作伙伴Windward Bio启动SKB378/WIN378三期临床研究，探索一年两次给药方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1123875780","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123875780?lang=zh_cn&edition=full","pubTime":"2026-09-08 20:07","pubTimestamp":1788869230,"startTime":"0","endTime":"0","summary":"科伦博泰生物（06990.HK）宣布，其合作伙伴Windward Bio已正式启动SKB378/WIN378的三期临床研究。值得注意的是，该研究将重点评估一年两次给药方案的疗效与安全性——这一剂量策略的推进，标志着这款在研药物在给药便利性方面迈出了重要一步。SKB378/WIN378作为一种备受关注的生物制剂，此次三期研究的启动，不仅意味着其临床开发进程进入关键阶段，也为未来可能的患者用药体验改善奠定了基础。Windward Bio方面表示，选择一年两次的给药频率，旨在平衡持续疗效与用药依从性之间的需求。对于科伦博泰生物而言，这一进展也进一步彰显了其管线资产的外部合作价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0196878994.USD","06990","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166861904","title":"科伦博泰生物SKB378/WIN378耐受性良好，未出现治疗相关严重不良事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1166861904","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166861904?lang=zh_cn&edition=full","pubTime":"2026-09-08 20:06","pubTimestamp":1788869168,"startTime":"0","endTime":"0","summary":"科伦博泰生物制药股份有限公司近日公布，其研发的SKB378/WIN378药物展现出良好的耐受性。在临床研究中，该药物未引发任何与治疗相关的严重不良事件，这一结果为后续研发工作奠定了坚实基础。安全性数据的积极表现，无疑为这款候选药物注入了更强信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0196878994.USD","BK1161","06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320101","title":"科伦博泰生物(06990)：SKB378/WIN378治疗哮喘的2期临床取得阳性结果及3期研究启动","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320101","media":"智通财经","labels":["productRelease"],"top":1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665320101?lang=zh_cn&edition=full","pubTime":"2026-09-08 20:05","pubTimestamp":1788869122,"startTime":"0","endTime":"0","summary":"研究亦同时评估SKB378/WIN378对肺功能和气道炎症生物标志物的影响。3期部分正在评估两种每年两次给药剂量的SKB378/WIN378对比安慰剂的疗效，主要终点为重度哮喘患者的年化哮喘急性发作率。SKB378/WIN378耐受性及安全性良好，截至数据截止日期，未观察到治疗相关严重不良事件、退出或停药。注射部位反应发生率低于1%，抗药物抗体发生率为2%。SKB378/WIN378最初由公司与和铂医药控股有限公司共同开发，双方共同享有其全球权益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493527.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"科伦博泰生物(06990)：SKB378/WIN378治疗哮喘的2期临床取得阳性结果及3期研究启动","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06990","LU0196878994.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169674417","title":"科伦博泰合作伙伴Windward Bio公布SKB378/WIN378哮喘二期临床积极结果，并启动三期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1169674417","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169674417?lang=zh_cn&edition=full","pubTime":"2026-09-08 20:01","pubTimestamp":1788868875,"startTime":"0","endTime":"0","summary":"科伦博泰生物的合作伙伴Windward Bio近日宣布，其在研药物SKB378/WIN378针对哮喘适应症的二期临床试验取得了积极结果，并基于此正式启动了三期临床研究。这一进展为哮喘治疗领域带来了新的曙光。SKB378/WIN378作为双方合作管线中的核心资产，其临床价值正逐步得到验证。哮喘作为一种影响全球数亿患者的慢性呼吸道疾病，现有治疗手段仍存在未满足的临床需求，SKB378/WIN378若能在后续研究中持续验证其优势，或将为患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0196878994.USD","BK1161","06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156391309","title":"科伦博泰生物：东方证券股份有限公司减持，好仓比例降至4.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=1156391309","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156391309?lang=zh_cn&edition=full","pubTime":"2026-09-04 17:42","pubTimestamp":1788514953,"startTime":"0","endTime":"0","summary":"东方证券股份有限公司于2026年8月28日以每股均价514.6015港元卖出科伦博泰生物股份1.97万股，涉资约1013.76万港元。东方证券股份有限公司此次减持前持有科伦博泰生物好仓886.01万股，占比5.01%；减持后持股量为884.04万股，好仓比例降至4.99%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169955832","title":"科伦博泰生物：东方证券股份有限公司增持，好仓比例升至5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=1169955832","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169955832?lang=zh_cn&edition=full","pubTime":"2026-09-04 17:41","pubTimestamp":1788514913,"startTime":"0","endTime":"0","summary":"东方证券股份有限公司于2026年8月31日以每股均价492.91港元买入科伦博泰生物股份3.08万股，涉资约1518.16万港元。东方证券股份有限公司此次增持前持有科伦博泰生物好仓884.04万股，占比4.99%；增持后持股量为887.12万股，好仓比例升至5.01%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664238859","title":"【券商聚焦】交银国际：医药行业收入稳健增长 多重利好推动盈利表现显著改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2664238859","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664238859?lang=zh_cn&edition=full","pubTime":"2026-09-04 09:00","pubTimestamp":1788483634,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，1H26港股/A股医药行业整体收入增长4.7%/3.2%。创新药产业链增速领跑行业，服务板块复苏：1）港股/A股CXO收入整体增长29.2%/25.3%，（扣非）净利润增长23.4%/67.6%，在各子板块中增速最快，行业整体景气度和订单需求处于高位。2）核心成药板块收入增长17.8%/3.4%、利润增长62.7%/35.0%。其中生物药增速远超化药，在板块收入中的占比也进一步提升。3）医院、器械、诊断、疫苗等板块业绩有复苏趋势。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1990646","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801","IE00B0JY6N72.USD","01951","KURE","09926","LU0315179316.USD","01276","LU0039217434.USD","03329","06160","02269","03759","LU1242518857.USD","HK0000320264.USD","01952","HK0000306685.HKD","02162","LU0327786744.USD","02268","BK1161","BK1589","01530","02596","BK1515","01093","06821","IE00B543WZ88.USD","LU0588546209.SGD","09966","BK1209","SG9999004220.SGD","06990","03692","LU0307460666.USD","02096","LU1251922891.USD","06996","KCE","LU2543165471.USD","LU1880383366.USD","LU0348783233.USD","IE00B5MMRT66.SGD","01177","06078","02273","LU1152091168.USD","LU0856984785.SGD","09996","01548","00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664879489","title":"汇添富基金管理股份有限公司增持科伦博泰生物(06990)3.08万股 每股作价约492.91港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2664879489","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664879489?lang=zh_cn&edition=full","pubTime":"2026-09-03 19:17","pubTimestamp":1788434252,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，8月31日，汇添富基金管理股份有限公司增持科伦博泰生物(06990)3.08万股，每股作价492.9088港元，总金额约为1518.16万港元。增持后最新持股数目为887.12万股，最新持股比例为5.01%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491697.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","LU0196878994.USD","BK1161","06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197323262","title":"科伦博泰生物：汇添富基金管理股份有限公司增持，好仓比例升至5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=1197323262","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197323262?lang=zh_cn&edition=full","pubTime":"2026-09-03 17:19","pubTimestamp":1788427153,"startTime":"0","endTime":"0","summary":"汇添富基金管理股份有限公司于2026年8月31日以每股均价492.9088港元买入科伦博泰生物（06990）H股3.08万股，涉资约1518.16万港元。汇添富基金管理股份有限公司此次增持前持有科伦博泰生物好仓884.04万股，占比4.99%；增持后持股量为887.12万股，好仓比例升至5.01%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123637054","title":"科伦博泰生物8月股份变动月报表，股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1123637054","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123637054?lang=zh_cn&edition=full","pubTime":"2026-09-03 16:36","pubTimestamp":1788424590,"startTime":"0","endTime":"0","summary":"四川科伦博泰生物医药股份有限公司于2026年9月3日发布公告，披露截至2026年8月31日的股份变动月报表。根据公告，报告期内公司法定/注册股本维持为人民币239,023,969元，其中包括176,822,257股面值为每股人民币1元的H股和62,201,712股面值为每股人民币1元的内资股，未发生增减变动。公司表示，现有股本规模满足香港联交所相关公众持股量要求，各项业务及股本状况均保持稳定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130601247","title":"科伦博泰生物：汇添富基金管理股份有限公司减持，好仓比例降至4.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=1130601247","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130601247?lang=zh_cn&edition=full","pubTime":"2026-09-02 17:25","pubTimestamp":1788341138,"startTime":"0","endTime":"0","summary":"汇添富基金管理股份有限公司于2026年8月28日以每股均价514.6015港元卖出1.97万股科伦博泰生物股份，涉资约1013.76万港元。汇添富基金管理股份有限公司此次减持前持有科伦博泰生物好仓886.01万股，占比5.01%；减持后持股量为884.04万股，好仓比例降至4.99%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664817446","title":"【生物医药小白投研】第七篇：看得懂基本面，更要把握交易节奏","url":"https://stock-news.laohu8.com/highlight/detail?id=2664817446","media":"港股解码","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664817446?lang=zh_cn&edition=full","pubTime":"2026-09-02 15:48","pubTimestamp":1788335280,"startTime":"0","endTime":"0","summary":"很多投资者的通病：基本面研究很透彻，看得懂管线、分得清BD、看得懂估值，但实操交易却总是不得要领。2）建议卖点：预期兑现、情绪高位重大临床数据落地、BD正式签约、药物获批等核心利好兑现；股价短期大幅拉升、估值透支未来预期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzI2MDAzMTQ4OA==&mid=2650514068&idx=1&sn=04383d6542345b5ab37bff46d0980044&chksm=f3c9956fce9a29e7b20b133d9a101d486e4af7867027ae7c06fa93bfeea19f07b272ba5bb04e&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["LU0326950275.SGD","LU0417516738.SGD","LU2097828714.EUR","LU2476274720.SGD","IE00BPRC5H50.USD","LU2488822045.USD","LU1188198961.HKD","IE00B5MMRT66.SGD","LU1961090484.USD","LU0348766576.USD","LU0463099449.HKD","LU0588546209.SGD","LU1770034418.SGD","KURE","LU0348783233.USD","LU0348827113.USD","LU0417516902.SGD","LU0348784397.USD","LU0348825331.USD","LU1969619763.USD","06990","LU2476274308.USD","LU2097828557.USD","LU2778985437.USD","LU0634319403.HKD","LU2097828474.EUR","LU2097828631.EUR","IE00B543WZ88.USD","LU2097828805.USD","06160","01801","LU1719994722.HKD","LU1303224171.USD","LU0228659784.USD","BK1589","09926","LU0561508036.HKD","BK1500","HK0000165453.HKD","LU1794554557.SGD","LU0196878994.USD","LU1720050803.USD","LU0455707207.USD","BK1588","BK1574","LU0307460666.USD","LU0502904849.HKD","LU0828237510.HKD","LU2242644610.SGD","LU0348767384.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182577008","title":"异动解读｜科伦博泰生物盘中下跌3.4%，报503.0港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1182577008","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182577008?lang=zh_cn&edition=full","pubTime":"2026-08-31 09:38","pubTimestamp":1788140327,"startTime":"0","endTime":"0","summary":"8月31日，科伦博泰生物盘中下跌3.4%，报503.0港元/股，成交额1326.44万港元。科伦博泰生物所在的生物科技行业整体承压，个股中，康希诺生物跌6.74%，百济神州跌3.21%，康方生物跌2.78%，信达生物跌2.23%，云顶新耀跌1.96%。科伦博泰生物主要从事肿瘤学、免疫学及其他治疗领域的创新药物研发、制造及商业化，核心产品包括TROP2 ADC芦康沙妥珠单抗等抗体药物偶联物。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662094216","title":"【生物医药小白投研】第五篇：读懂BD的价值逻辑","url":"https://stock-news.laohu8.com/highlight/detail?id=2662094216","media":"港股解码","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662094216?lang=zh_cn&edition=full","pubTime":"2026-08-28 16:50","pubTimestamp":1787907000,"startTime":"0","endTime":"0","summary":"在生物医药二级市场，BD是出现频率最高、对股价影响较为直接的核心词汇之一。但在A股、港股创新药赛道，能够对股价形成重大催化的BD交易，大多特指药物全球权益授权交易。首付款是海外顶级药企对药物当下真实价值的投票，是BD含金量的核心判断依据。BD出海让一款药物同时覆盖国内+全球市场，估值逻辑彻底升级。例如科伦博泰、信达生物等，持续兑现出海BD，研发实力全球认可。NO.6小白必须警惕以下BD误区误区一：BD落地股价必涨。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzI2MDAzMTQ4OA==&mid=2650514013&idx=2&sn=a94c778f97f0744682cc347b39421f20&chksm=f382c39a6e71d39b1967e69c7fe65ec399f4658e5a18b93c3b2c95e183487c32d8cdc7dd65d9&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["06160","KURE","LU0502904849.HKD","ONC","LU1770034418.SGD","LU2097828631.EUR","LU1303224171.USD","BK1588","BK1583","LU2097828557.USD","LU0828237510.HKD","06990","LU0307460666.USD","LU0196878994.USD","LU1188198961.HKD","LU2242644610.SGD","01801","BK1593","LU1251922891.USD","LU0463099449.HKD","688235","LU2097828714.EUR","LU2097828805.USD","LU1969619763.USD","BK1589","LU0455707207.USD","LU1719994722.HKD","BK1161","LU2097828474.EUR","01530","LU0244354667.USD","BK1500","LU0326950275.SGD","LU2328871848.SGD","LU0588546209.SGD","LU2488822045.USD","HK0000165453.HKD","LU0228659784.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192810746","title":"异动解读｜科伦博泰生物盘中下跌3.16%，报521.0港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1192810746","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192810746?lang=zh_cn&edition=full","pubTime":"2026-08-24 10:43","pubTimestamp":1787539437,"startTime":"0","endTime":"0","summary":"8月24日，科伦博泰生物盘中下跌3.16%，报521.0港元/股，成交额7350.27万港元。科伦博泰生物所在的生物科技行业中，板块整体表现偏弱，个股中，云顶新耀涨1.34%，康方生物跌1.33%，信达生物跌3.17%，百济神州跌3.51%，康希诺生物跌4.48%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661412492","title":"科伦博泰半年报首盈背后：一位75岁创业者的向上之路","url":"https://stock-news.laohu8.com/highlight/detail?id=2661412492","media":"锦缎","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661412492?lang=zh_cn&edition=full","pubTime":"2026-08-24 07:28","pubTimestamp":1787527680,"startTime":"0","endTime":"0","summary":"8月17日，科伦博泰生物发布2026年中期业绩。这是科伦博泰上市以来首次实现半年度盈利。站在这一里程碑前的，是75岁的刘革新。03118亿美元与兑现科伦博泰真正的拐点，出现在2022年。一旦递交，科伦博泰将触发新的里程碑付款，并开启长期销售分成窗口。科伦博泰的战略高度依赖刘革新个人的判断力。75岁的刘革新还在前线，科伦博泰的“向上”，也还在路上。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8vqEVRQntVo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"ifeng_tech","symbols":["BK1161","LU0196878994.USD","06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660020034","title":"mRNA癌症疫苗实现历史性突破 易方达生物医药ETF(03186)港美股双布局捕捉创新红利","url":"https://stock-news.laohu8.com/highlight/detail?id=2660020034","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660020034?lang=zh_cn&edition=full","pubTime":"2026-08-20 16:45","pubTimestamp":1787215545,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，8月19日，Moderna与默沙东公布，个人化mRNA癌症疫苗联合Keytruda，在黑色素瘤三期试验期中分析达标。截至2026年8月20日，易方达生物医药ETF  是港交所上市生物医药主题ETF中，唯一同时配置港股及美股生物医药成分的产品。这些成份股的均衡配置，让该ETF能够捕捉医药板块的整体修复行情。本次mRNA癌症疫苗达标，再次说明医疗创新本身就是科技突破，而不只是防御型板块。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482590.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2488822045.USD","LU0196878994.USD","BK1583","09688","03186","06990","BK1588","159929","BK1574","02162","159646","BK1587","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://kelun-biotech.com","stockEarnings":[{"period":"1week","weight":-0.0037},{"period":"1month","weight":-0.0955},{"period":"3month","weight":0.2157},{"period":"6month","weight":0.2577},{"period":"1year","weight":-0.0731},{"period":"ytd","weight":0.2443}],"compareEarnings":[{"period":"1week","weight":-0.0005},{"period":"1month","weight":-0.0137},{"period":"3month","weight":0.0373},{"period":"6month","weight":-0.0155},{"period":"1year","weight":-0.0124},{"period":"ytd","weight":-0.0122}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"四川科伦博泰生物医药股份有限公司是一家主要从事新药业务的研发、生产和销售的中国公司。该公司主要从事肿瘤学、免疫学及其他治疗领域的创新药物的研发、制造及商业化。该公司的产品有抗体药物偶联物（ADC）SKB264和A166等。该公司产品主要用于乳腺癌、非小细胞肺癌、胃肠道癌等疾病的治疗。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.05939},{"month":2,"riseRate":0.666667,"avgChangeRate":0.239909},{"month":3,"riseRate":1,"avgChangeRate":0.292496},{"month":4,"riseRate":1,"avgChangeRate":0.083557},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.011152},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.022649},{"month":7,"riseRate":0.666667,"avgChangeRate":0.111158},{"month":8,"riseRate":1,"avgChangeRate":0.042518},{"month":9,"riseRate":0.75,"avgChangeRate":0.058951},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.03489},{"month":11,"riseRate":1,"avgChangeRate":0.072292},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.053467}],"exchange":"SEHK","name":"科伦博泰生物","nameEN":"SKB BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科伦博泰生物(06990)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科伦博泰生物(06990)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科伦博泰生物,06990,科伦博泰生物股票,科伦博泰生物股票老虎,科伦博泰生物股票老虎国际,科伦博泰生物行情,科伦博泰生物股票行情,科伦博泰生物股价,科伦博泰生物股市,科伦博泰生物股票价格,科伦博泰生物股票交易,科伦博泰生物股票购买,科伦博泰生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科伦博泰生物(06990)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科伦博泰生物(06990)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}